Source: PharmaLive
Area: News
According to a Pharmalive report, the US Food and Drug Administration (FDA) has approved tafluprost (ZioptanT) preservative-free ophthalmic solution) for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.
The FDA approval of tafluprost was based on efficacy and safety results from five controlled clinical studies of up to two years in 905 patients evaluating both preservative-containing and preservative-free formulations of tafluprost. The studies demonstrated that tafluprost, dosed once-daily in the evening, lowered IOP at three and six months by (Read more...)
Uncategorized